Literature DB >> 7701463

AIDS and the lung: update 1995. 1. Pneumocystis carinii pneumonia.

R F Miller1, D M Mitchell.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7701463      PMCID: PMC473924          DOI: 10.1136/thx.50.2.191

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  68 in total

1.  Seasonal incidence of Pneumocystis carinii pneumonia.

Authors:  P Vanhems; B Hirschel; A Morabia
Journal:  Lancet       Date:  1992-05-09       Impact factor: 79.321

2.  Pneumocystis carinii organisms derived from rat and human hosts are genetically distinct.

Authors:  K Sinclair; A E Wakefield; S Banerji; J M Hopkin
Journal:  Mol Biochem Parasitol       Date:  1991-03       Impact factor: 1.759

3.  Serial pulmonary function tests in the diagnosis of P. carinii pneumonia.

Authors:  D M Mitchell; J Fleming; J R Harris; R J Shaw
Journal:  Eur Respir J       Date:  1993-06       Impact factor: 16.671

4.  Molecular genetic distinction of Pneumocystis carinii from rats and humans.

Authors:  J R Stringer; S L Stringer; J Zhang; R Baughman; A G Smulian; M T Cushion
Journal:  J Eukaryot Microbiol       Date:  1993 Nov-Dec       Impact factor: 3.346

5.  Amount of Pneumocystis carinii and degree of acute lung inflammation in HIV-associated P carinii pneumonia.

Authors:  J Vestbo; T L Nielsen; J Junge; J D Lundgren
Journal:  Chest       Date:  1993-07       Impact factor: 9.410

6.  Fungus-specific translation elongation factor 3 gene present in Pneumocystis carinii.

Authors:  M F Ypma-Wong; W A Fonzi; P S Sypherd
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

7.  Diagnostic utility of lactate dehydrogenase levels in patients receiving aerosolized pentamidine.

Authors:  D P Meeker; G A Matysik; K Stelmach; S Rehm
Journal:  Chest       Date:  1993-08       Impact factor: 9.410

8.  Clindamycin/primaquine versus trimethoprim-sulfamethoxazole as primary therapy for Pneumocystis carinii pneumonia in AIDS: a randomized, double-blind pilot trial.

Authors:  E Toma; S Fournier; M Dumont; P Bolduc; H Deschamps
Journal:  Clin Infect Dis       Date:  1993-08       Impact factor: 9.079

9.  Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group.

Authors:  P M Girard; R Landman; C Gaudebout; R Olivares; A G Saimot; P Jelazko; C Gaudebout; A Certain; F Boué; E Bouvet
Journal:  N Engl J Med       Date:  1993-05-27       Impact factor: 91.245

10.  Indium-111-labeled polyclonal human immunoglobulin: identifying focal infection in patients positive for human immunodeficiency virus.

Authors:  J R Buscombe; W J Oyen; A Grant; R A Claessens; J van der Meer; F H Corstens; P J Ell; R F Miller
Journal:  J Nucl Med       Date:  1993-10       Impact factor: 10.057

View more
  6 in total

1.  The management of Pneumocystis carinii pneumonia.

Authors:  F J Vilar; S H Khoo; T Walley
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

Review 2.  The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction.

Authors: 
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

3.  Interactions between opportunistic micro-organisms and HIV in the lung.

Authors:  J R Clarke; D Israel-Biet
Journal:  Thorax       Date:  1996-09       Impact factor: 9.139

Review 4.  Virulence factors of medically important fungi.

Authors:  L H Hogan; B S Klein; S M Levitz
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

5.  Isolation of rat dihydrofolate reductase gene and characterization of recombinant enzyme.

Authors:  Y Wang; J A Bruenn; S F Queener; V Cody
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

6.  Naturally acquired Pneumocystis carinii pneumonia in gene disruption mutant mice: roles of distinct T-cell populations in infection.

Authors:  R Hanano; K Reifenberg; S H Kaufmann
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.